SCLX Stock Overview
Focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Scilex Holding Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$2.63 |
| 52 Week Low | US$0.73 |
| Beta | 1.19 |
| 11 Month Change | -18.03% |
| 3 Month Change | -43.98% |
| 1 Year Change | -36.71% |
| 33 Year Change | -90.00% |
| 5 Year Change | n/a |
| Change since IPO | -89.85% |
Recent News & Updates
Recent updates
Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically
Jun 14
It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks
Apr 24Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues
Feb 28Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)
Dec 21Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings
May 06Shareholder Returns
| SCLX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -13.0% | 0.05% | 1.6% |
| 1Y | -36.7% | 22.0% | 30.6% |
Return vs Industry: SCLX underperformed the US Pharmaceuticals industry which returned 21.8% over the past year.
Return vs Market: SCLX underperformed the US Market which returned 30.5% over the past year.
Price Volatility
| SCLX volatility | |
|---|---|
| SCLX Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCLX's share price has been volatile over the past 3 months.
Volatility Over Time: SCLX's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 113 | Jaisim Shah | www.scilexholding.com |
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia.
Scilex Holding Company Fundamentals Summary
| SCLX fundamental statistics | |
|---|---|
| Market cap | US$131.72m |
| Earnings (TTM) | -US$171.53m |
| Revenue (TTM) | US$50.83m |
2.6x
P/S Ratio-0.8x
P/E RatioIs SCLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCLX income statement (TTM) | |
|---|---|
| Revenue | US$50.83m |
| Cost of Revenue | US$16.14m |
| Gross Profit | US$34.69m |
| Other Expenses | US$206.22m |
| Earnings | -US$171.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 68.24% |
| Net Profit Margin | -337.44% |
| Debt/Equity Ratio | -48.6% |
How did SCLX perform over the long term?
See historical performance and comparison